Impact of M2BPGi on the Hepatocarcinogenesis After the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2021 Jul 2

PMID 34201309

Citations 1

Authors

Satoshi Takakusagi

Ken Sato

Kyoko Marubashi

Kazuko Kizawa

Takashi Kosone

Satoru Kakizaki

Hitoshi Takagi

Toshio Uraoka

Affiliations

Soon will be listed here.

Abstract

The clinical significance of mac-2 binding protein glycosylation isomer (M2BPGi) levels based on virological responses due to antiviral therapy has not been fully evaluated. We compared the change before and 24 weeks after the therapy with daclatasvir and asunaprevir (DCV+ASV) of M2BPGi levels with those of other fibrosis markers in 73 chronic hepatitis C cases. Moreover, we examined the association between M2BPGi levels and hepatocarcinogenesis in sustained virological response (SVR) and non-SVR cases. M2BPGi levels were significantly improved at post-treatment week 24 (PTW24) in SVR but not non-SVR cases, whereas the changes of other fibrosis markers showed the same tendency in both SVR and non-SVR cases. M2BPGi levels were well correlated with other fibrosis markers at baseline but not PTW24. The incidence of hepatocellular carcinoma (HCC) was significantly associated with M2BPGi levels at PTW24. The achievement of SVR significantly affected the improvement of M2BPGi levels that best reflected the effect of direct-acting antivirals among the fibrosis markers. Furthermore, M2BPGi levels at PTW24 were also associated with the incidence of HCC in only SVR cases. However, the rapid decrease of M2BPGi levels might reflect the amelioration of liver inflammation rather than the improvement of liver fibrosis, which should be further elucidated.

Citing Articles

Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD.

Hanamatsu H, Suda G, Ohara M, Ogawa K, Tamaki N, Hikita H J Gastroenterol. 2025; .

PMID: 39849179 DOI: 10.1007/s00535-024-02206-8.

Comparison of Efficacy between Pemafibrate and Omega-3-Acid Ethyl Ester in the Liver: the PORTRAIT Study.

Sumida Y, Toyoda H, Yasuda S, Kimoto S, Sakamoto K, Nakade Y J Atheroscler Thromb. 2024; 31(11):1620-1633.

PMID: 38777770 PMC: 11537790. DOI: 10.5551/jat.64896.

References

Akuta N, Sezaki H, Suzuki F, Kawamura Y, Hosaka T, Kobayashi M . Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older. J Med Virol. 2016; 89(1):91-98. DOI: 10.1002/jmv.24592. View

Chayama K, Suzuki F, Karino Y, Kawakami Y, Sato K, Atarashi T . Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2017; 53(4):557-565. PMC: 5866824. DOI: 10.1007/s00535-017-1391-5. View

Tsuji K, Kurosaki M, Itakura J, Mori N, Takaki S, Hasebe C . Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol. 2018; 53(10):1142-1150. DOI: 10.1007/s00535-018-1455-1. View

Kanwal F, Kramer J, Asch S, Chayanupatkul M, Cao Y, El-Serag H . Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017; 153(4):996-1005.e1. DOI: 10.1053/j.gastro.2017.06.012. View

Miyaki E, Imamura M, Hiraga N, Murakami E, Kawaoka T, Tsuge M . Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol Res. 2015; 46(8):758-64. DOI: 10.1111/hepr.12621. View

Inoue T, Tsuzuki Y, Iio E, Shinkai N, Matsunami K, Fujiwara K . Clinical Evaluation of Hepatocarcinogenesis and Outcome Using a Novel Glycobiomarker Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA-M2BP) in Chronic Hepatitis C with Advanced Fibrosis. Jpn J Infect Dis. 2018; 71(3):177-183. DOI: 10.7883/yoken.JJID.2017.459. View

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

Asahina Y, Itoh Y, Ueno Y, Matsuzaki Y, Takikawa Y, Yatsuhashi H . Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection. Liver Int. 2018; 38(9):1552-1561. DOI: 10.1111/liv.13685. View

Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S . A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013; 3:1065. PMC: 3545220. DOI: 10.1038/srep01065. View

10.

Sato S, Genda T, Ichida T, Amano N, Sato S, Murata A . Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein. Int J Mol Sci. 2016; 17(12). PMC: 5187943. DOI: 10.3390/ijms17122143. View

11.

Bachofner J, Valli P, Kroger A, Bergamin I, Kunzler P, Baserga A . Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int. 2016; 37(3):369-376. DOI: 10.1111/liv.13256. View

12.

Seike T, Komura T, Shimizu Y, Omura H, Kumai T, Kagaya T . The Serum Mac-2-binding Protein Glycosylation Isomer Dynamics in Acute Liver Injury. Intern Med. 2020; 59(13):1581-1588. PMC: 7402970. DOI: 10.2169/internalmedicine.3867-19. View

13.

Wai C, Greenson J, Fontana R, Kalbfleisch J, Marrero J, Conjeevaram H . A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38(2):518-26. DOI: 10.1053/jhep.2003.50346. View

14.

Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y . Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2. J Med Virol. 2017; 89(9):1567-1573. DOI: 10.1002/jmv.24776. View

15.

Osawa L, Tamaki N, Kurosaki M, Kirino S, Watakabe K, Wang W . Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor. Int J Mol Sci. 2020; 21(10). PMC: 7279305. DOI: 10.3390/ijms21103640. View

16.

Tateyama M, Yatsuhashi H, Taura N, Motoyoshi Y, Nagaoka S, Yanagi K . Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2010; 46(1):92-100. DOI: 10.1007/s00535-010-0293-6. View

17.

Yasui Y, Kurosaki M, Komiyama Y, Takada H, Tamaki N, Watakabe K . Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. Hepatol Res. 2018; 48(13):1131-1139. DOI: 10.1111/hepr.13233. View

18.

Ioannou G, Green P, Beste L, Mun E, Kerr K, Berry K . Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J Hepatol. 2018; 69(5):1088-1098. PMC: 6201746. DOI: 10.1016/j.jhep.2018.07.024. View

19.

Morio K, Imamura M, Daijo K, Teraoka Y, Honda F, Nakamura Y . Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury. J Gastroenterol. 2017; 52(12):1252-1257. DOI: 10.1007/s00535-017-1345-y. View

20.

Vanderschaeghe D, Laroy W, Sablon E, Halfon P, Van Hecke A, Delanghe J . GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics. 2009; 8(5):986-94. PMC: 2689777. DOI: 10.1074/mcp.M800470-MCP200. View